alexa Clinical Next-Generation Sequencing for Somatic Mutation Detection- Advancements and Commercialization Strategies | OMICS International | Abstract
ISSN: 2572-5645

Advances in Molecular Diagnostics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article

Clinical Next-Generation Sequencing for Somatic Mutation Detection- Advancements and Commercialization Strategies

Andrew Hesse, Christopher Chen and Honey V. Reddi*
Transgenomic, Inc, 5 Science Park, New Haven, CT, USA 06477.
Corresponding Author : Honey V. Reddi
Transgenomic, Inc, 5 Science Park, New Haven, CT, USA 06477
Tel: 203-907-2290
E-mail: [email protected]
Received: September 29, 2015; Accepted: October 24, 2015; Published: October 27, 2015
Citation: Hesse A, Chen C, Reddi HV (2015) Clinical Next-Generation Sequencing for Somatic Mutation Detection – Advancements and Commercialization Strategies. Adv Mol Diag 1:101. doi:10.4172/AMD.1000101
Copyright: © 2015 Hesse A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Abstract

Advancements in next-generation sequencing, variant-calling software, and mutation enrichment are facilitating the detection of rare genetic variants. In doing so, these methods have enabled identification of somatic disease, and more specifically cancer, representing as little as 0.01% of bulk genetic material. This improved sensitivity reduces false negative results, and in cancer, allows earlier detection. Such early detection will greatly improve monitoring and treatment of these diseases, especially in the context of liquid biopsies. This review aims to encapsulate the growing spectrum of technology and software currently being utilized to improve the sensitivity of somatic variant detection. Furthermore, industry adoption of these techniques will be summarized.

Keywords

Leave Your Message 24x7
Top